home / stock / bolt / bolt quote
Last: | $1.12 |
---|---|
Change Percent: | -2.7% |
Open: | $1.14 |
Close: | $1.12 |
High: | $1.14 |
Low: | $1.09 |
Volume: | 25,497 |
Last Trade Date Time: | 04/29/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.12 | $1.14 | $1.12 | $1.14 | $1.09 | 25,497 | 04-29-2024 |
$1.11 | $1.2 | $1.11 | $1.2 | $1.1 | 122,489 | 04-26-2024 |
$1.16 | $1.2 | $1.16 | $1.21 | $1.15 | 13,475 | 04-25-2024 |
$1.2002 | $1.1 | $1.2002 | $1.21 | $1.09 | 154,904 | 04-24-2024 |
$1.11 | $1.09 | $1.11 | $1.12 | $1.09 | 50,503 | 04-23-2024 |
$1.11 | $1.11 | $1.11 | $1.13 | $1.09 | 39,426 | 04-22-2024 |
$1.11 | $1.15 | $1.11 | $1.16 | $1.11 | 55,054 | 04-19-2024 |
$1.14 | $1.14 | $1.14 | $1.16 | $1.11 | 90,067 | 04-18-2024 |
$1.11 | $1.14 | $1.11 | $1.15 | $1.11 | 74,531 | 04-17-2024 |
$1.15 | $1.15 | $1.15 | $1.15 | $1.08 | 101,723 | 04-16-2024 |
$1.13 | $1.19 | $1.13 | $1.2 | $1.12 | 174,826 | 04-15-2024 |
$1.2 | $1.25 | $1.2 | $1.28 | $1.17 | 338,930 | 04-12-2024 |
$1.27 | $1.24 | $1.27 | $1.2799 | $1.24 | 52,957 | 04-11-2024 |
$1.25 | $1.28 | $1.25 | $1.288 | $1.24 | 71,364 | 04-10-2024 |
$1.285 | $1.36 | $1.285 | $1.36 | $1.22 | 152,547 | 04-09-2024 |
$1.37 | $1.35 | $1.37 | $1.3999 | $1.32 | 54,158 | 04-08-2024 |
$1.33 | $1.37 | $1.33 | $1.37 | $1.32 | 28,752 | 04-05-2024 |
$1.33 | $1.35 | $1.33 | $1.36 | $1.32 | 42,197 | 04-04-2024 |
$1.35 | $1.37 | $1.35 | $1.48 | $1.3 | 203,324 | 04-03-2024 |
$1.4 | $1.44 | $1.4 | $1.4799 | $1.36 | 237,234 | 04-02-2024 |
News, Short Squeeze, Breakout and More Instantly...
Bolt Biotherapeutics Inc. Company Name:
BOLT Stock Symbol:
NASDAQ Market:
– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones – BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts – Cash balanc...
REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will present a company overview at the TD Cowen 44 th Annual He...
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization...